Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03842969




Registration number
NCT03842969
Ethics application status
Date submitted
11/02/2019
Date registered
15/02/2019
Date last updated
31/08/2023

Titles & IDs
Public title
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
Scientific title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease
Secondary ID [1] 0 0
2018-003898-94
Secondary ID [2] 0 0
BN40955
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Huntington Disease 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - RO7234292 (RG6042)

Experimental: RO7234292 (RG6042) Q8W - Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.

Experimental: RO7234292 (RG6042) Q16W - Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.


Treatment: Drugs: RO7234292 (RG6042)
Intrathecal injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Treatment Emergent Adverse Events
Timepoint [1] 0 0
Up to Approximately 3 Years
Primary outcome [2] 0 0
Number of Participants With Suicidal Ideation, Suicidal Behavior, and Self-Injurious Behavior Without Suicidal Intent Based on the Columbia Suicide Severity Rating Scale (C-SSRS)
Timepoint [2] 0 0
Up to approximately 3 Years
Primary outcome [3] 0 0
Change From Baseline in Cognition, Using Montreal Cognitive Assessment (MoCA)
Timepoint [3] 0 0
Up to Approximately 3 Years

Eligibility
Key inclusion criteria
- Prior enrollment in a Roche-sponsored or Genentech-sponsored study in HD for the
RO7234292 (RG6042) development program that made provision for entry into an OLE study

- For women of childbearing potential: agreement to remain abstinent or use
contraceptive measures

- For men: agreement to remain abstinent or use a condom, and agreement to refrain from
donating sperm

- Patients who were screened and eligible for the placebo-controlled Phase III Study
BN40423 but could not be randomized prior to the close of Study BN40423 enrollment due
to challenges relating to the COVID-19 pandemic

Inclusion criteria of patients who were screened and eligible for the placebo-controlled
Phase III Study BN40423 but could not be randomized prior to the close of Study BN40423
enrollment due to challenges relating to the COVID-19 pandemic:

- Manifest HD diagnosis, defined as a DCL score of 4

- Independence Scale (IS) score >=70

- Genetically confirmed disease by direct DNA testing with a CAP score >400

- Clinical assessment to ensure individual has intact functional independence at
baseline to maintain self-care and core activities of daily living (ADLs).
Minimum age
25 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Withdrawal of consent from the preceding study

- Permanent discontinuation of RO7234292 (RG6042) for any drug-related safety concern
during the preceding study or meeting of any study treatment discontinuation criteria
specified in the preceding study at the time of enrollment into this study

- An ongoing, unresolved, clinically significant medical problem that in the judgment of
the investigator would make it unsafe for the patient to participate in this study

- Antiplatelet or anticoagulant therapy within 14 days prior to inclusion or anticipated
use during the study, including, but not limited to, aspirin, clopidogrel,
dipyridamole, warfarin, dabigatran, rivaroxaban, and apixaban

- History of bleeding diathesis or coagulopathy

- Platelet count less than the lower limit of normal

- Concurrent participation in any therapeutic clinical trial

- Study treatment (RO7234292/RG6042) is commercially marketed in the patient's country
for the patient-specific disease and is accessible to the patient

- Pregnant or breastfeeding, or intending to become pregnant during the study or within
5 months after the final dose of study drug

Exclusion criteria of patients who were screened and eligible for the placebo-controlled
Phase III Study BN40423 but could not be randomized prior to the close of Study BN40423
enrollment due to challenges relation to the COVID-19 pandemic:

- Any serious medical condition or clinically significant laboratory, or vital sign
abnormality or claustrophobia at screening that, in the investigator's judgment,
precludes the patient's safe participation in and completion of the study

- Pregnant or breastfeeding, or intending to become pregnant during the study or within
5 months after the final dose of study drug

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/04/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/03/2022
Sample size
Target
Accrual to date
Final
236
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Austria
State/province [12] 0 0
Innsbruck
Country [13] 0 0
Canada
State/province [13] 0 0
British Columbia
Country [14] 0 0
Canada
State/province [14] 0 0
Ontario
Country [15] 0 0
Canada
State/province [15] 0 0
Quebec
Country [16] 0 0
Germany
State/province [16] 0 0
Berlin
Country [17] 0 0
Germany
State/province [17] 0 0
Bochum
Country [18] 0 0
Germany
State/province [18] 0 0
Ulm
Country [19] 0 0
Italy
State/province [19] 0 0
Lombardia
Country [20] 0 0
Italy
State/province [20] 0 0
Puglia
Country [21] 0 0
Netherlands
State/province [21] 0 0
Groningen
Country [22] 0 0
Netherlands
State/province [22] 0 0
Leiden
Country [23] 0 0
Spain
State/province [23] 0 0
Badajoz
Country [24] 0 0
Spain
State/province [24] 0 0
Barcelona
Country [25] 0 0
Spain
State/province [25] 0 0
Burgos
Country [26] 0 0
Spain
State/province [26] 0 0
Madrid
Country [27] 0 0
Spain
State/province [27] 0 0
Sevilla
Country [28] 0 0
United Kingdom
State/province [28] 0 0
Birmingham
Country [29] 0 0
United Kingdom
State/province [29] 0 0
Cambridge
Country [30] 0 0
United Kingdom
State/province [30] 0 0
Cardiff
Country [31] 0 0
United Kingdom
State/province [31] 0 0
London
Country [32] 0 0
United Kingdom
State/province [32] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in
participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or
Genentech-sponsored studies in the Huntington's disease (HD) in the development program for
RG6042.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03842969
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03842969